Development of a commercial assay for the rapid and general detection of PFAS in environmental matrices (phase i)

Ended Project Grant Awarded Last action

Award ID
R43ES030677
Recipient
Awarding agency
Obligated
$503,872

Award facts

Assistance listing
93.113 Environmental Health
Completion date
Funding
  • $335,872.64 Federal
  • $167,999.00 Non-federal
Place of performance
Oklahoma City, OK, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Polyfluoro- and perfluoroalkyl substances (PFAS) are a group of highly fluorinated alkanes. Members of this family are known to be persistent and bioaccumulative. PFAS are associated with unfavorable health outcomes in human and animal models. Several public health agencies as well as scientists have published articles that indicate the presence of PFAS in human blood, serum, milk, cord blood, and tissues. Currently, detection of about a dozen of these chemicals out of more than a thousand of this class is performed using lcms/MS. However, prior to analysis many purification steps are required to eliminate interfering species. Furthermore, the necessity of internal standards for the detection of PFAS, and the lack of pertinent internal standards dramatically reduces the scope of PFAS-detection. Currently, PFAS testing is a lengthy and costly undertaking that represents a major scientific bottleneck. Thus, there is an urgent need for a real-time detection technology that can sense a broad range of PFAS without pretreatment of sample, or expensive instrumentation. Implementation of such a product will allow better understanding of the fate of PFAS within the environment and their impact on human health. This proposal's objective is to develop the pre-treatment free detection of PFAS in environmental matrices by coupling the key fluorous phase property with a highly sensitive fluorescence technology. In phase 1, we will apply the specific fluorous-fluorous interaction strategy to provide the adequate selectivity to preclude any associated purification steps. Fluorous tethered fluorescent dyes will be covalently immobilized on a glass surface. Initially, prior to exposure to PFAS, these fluorescent dyes will exist as excimers resulting from their close proximity to each other, the fluorescent probe turns the fluorescence on. Upon exposure to PFAS analytes, the analytes will be sequestered to the fluorous region of the probe due to specific fluorous-fluorous affinity. This will cause a physical disruption of the excimers, resulting in the fluorescence turn off of the excimer and a simultaneous turn on of the monomer emission. To achieve the proposed goal, in phase i the following specific aims will be pursued: specific AIM1: 1) attachment of the fluorescent DYE to the fluorous molecule, 2) immobilization of fluorous-DYE array on glass surface, and 3) evaluation of fluorescence on-off of fluorous-DYE glass surface with PFAS-samples. Ultimately the approach developed here will lay the groundwork for the development of a product that is expected to enable a broad range of researchers to study many types of effects on human health caused by PFAS.

Transactions

Action Federal Non-federal Date
Amendment -$125 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $167,999 $0
Original award $167,999 $167,999

Quick answers

Who received award R43ES030677?

R43ES030677 was awarded to Weaver Labs LLC by National Institute of Environmental Health Sciences (National Institutes of Health) on April 1, 2021.

How much is award R43ES030677 worth?

$503,872 has been obligated on R43ES030677: $335,873 in federal funding and $167,999 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login